{"created":"2023-06-19T08:40:39.522318+00:00","id":7984,"links":{},"metadata":{"_buckets":{"deposit":"fa821ee9-5a15-4543-97c1-47498c06f8c7"},"_deposit":{"created_by":2,"id":"7984","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"7984"},"status":"published"},"_oai":{"id":"oai:gunma-u.repo.nii.ac.jp:00007984","sets":["719:760:761:796"]},"author_link":["30715","30716","30717","30714","30725","30727","30711","30712","30732","30726","30720","30719","30722","30718","30729","30733","30728","30709","30723","30708","30724","30710","30721","30731","30713","30730"],"item_6_alternative_title_18":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"A Newly Diagnosed CML-CP HBV Carrier was Safely Treated with Dasatinib and Entecavir"}]},"item_6_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-02-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"55","bibliographicPageStart":"51","bibliographicVolumeNumber":"64","bibliographic_titles":[{"bibliographic_title":"The Kitakanto medical journal = 北関東医学"}]}]},"item_6_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Takei, Hisashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Mitsui, Takeki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sato, Naru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Saito, Akio"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hoshino, Takumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Koiso, Hiromi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takizawa, Makiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yokohama, Akihiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Saito, Takayuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsukamoto, Norifumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Murakami, Hirokazu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Handa, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nojima, Yoshihisa"}],"nameIdentifiers":[{}]}]},"item_6_date_61":{"attribute_name":"更新日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2017-03-27","subitem_date_issued_type":"Created"}]},"item_6_description_39":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_6_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"症例は63歳男性. 血液検査, 骨髄検査から慢性骨髄性白血病慢性期(CML-CP) と診断した. 初診時よりHBV-DNA が検出され,HBVキャリアと診断した.チロシンキナーゼ阻害薬(TKI)投与によるHBV再活性化の可能性を考慮しentecavir 0.5mg/日の投与を先行した. HBV-DNA 量の低下を確認しdasatinib 100mg/日の併用を開始した. 投与3ヵ月後に細胞遺伝学的部分寛解, 12ヶ月後に分子生物学的大寛解を得た. 治療経過中HBV再活性化, 肝障害は認めず, 現在も併用療法継続中である. 近年, 免疫抑制作用を持つ薬剤によるHBV再活性化が報告されている. Dasatinibも免疫抑制作用を持つと考えられており, HBV再活性化の可能性が示唆される.HBVキャリアCML-CPに対し,entecavirとdasatinibを併用し安全に治療を継続し得た症例を経験したので報告する.","subitem_description_type":"Abstract"}]},"item_6_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"北関東医学会"}]},"item_6_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1343-2826","subitem_source_identifier_type":"ISSN"}]},"item_6_source_id_9":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN10585677","subitem_source_identifier_type":"NCID"}]},"item_6_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"武井, 寿史"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"三井, 健揮"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"佐藤, 成"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"斉藤, 明生"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"星野, 匠臣"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"小磯, 博美"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"滝沢, 牧子"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"横濱, 章彦"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"斉藤, 貴之"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"塚本, 憲史"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"村上, 博和"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"半田, 寛"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"野島, 美久"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-01-07"}],"displaytype":"detail","filename":"64_51.pdf","filesize":[{"value":"302.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"64_51.pdf","url":"https://gunma-u.repo.nii.ac.jp/record/7984/files/64_51.pdf"},"version_id":"e3077a22-7207-4172-8ac1-def74a83df1e"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"HBVキャリア","subitem_subject_scheme":"Other"},{"subitem_subject":"慢性骨髄性白血病","subitem_subject_scheme":"Other"},{"subitem_subject":"ダサチニブ","subitem_subject_scheme":"Other"},{"subitem_subject":"エンテカビル","subitem_subject_scheme":"Other"},{"subitem_subject":"HBV再活性化","subitem_subject_scheme":"Other"},{"subitem_subject":"hapatitis B virus (HBV) carrier","subitem_subject_scheme":"Other"},{"subitem_subject":"chronic myedoid leukemia (CML)","subitem_subject_scheme":"Other"},{"subitem_subject":"dasatinib","subitem_subject_scheme":"Other"},{"subitem_subject":"entecavir","subitem_subject_scheme":"Other"},{"subitem_subject":"HBV reactivation","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Entecavirとdasatinibを併用し，安全に治療継続し得たHBVキャリアの新規発症慢性骨髄性白血病慢性期","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Entecavirとdasatinibを併用し，安全に治療継続し得たHBVキャリアの新規発症慢性骨髄性白血病慢性期"},{"subitem_title":"A Newly Diagnosed CML-CP HBV Carrier was Safely Treated with Dasatinib and Entecavir","subitem_title_language":"en"}]},"item_type_id":"6","owner":"2","path":["796"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-02-27"},"publish_date":"2014-02-27","publish_status":"0","recid":"7984","relation_version_is_last":true,"title":["Entecavirとdasatinibを併用し，安全に治療継続し得たHBVキャリアの新規発症慢性骨髄性白血病慢性期"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-06-19T10:39:59.859387+00:00"}